Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010

► Health problems detected were comparable with baseline data of the districts. ► Documented safety profile consistent with monovalent PS conjugate vaccine (ex: Hib). ► No outstanding safety issue with MenAfriVac™. ► Hypersensitivity reactions require further assessment to rule out anaphylactic reactions.